Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-TB: PCR-guided TB treatment initiation
NCT02231229Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2014
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in Tuberculosis (TB), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients with treatment success at the end of TB treatment at 12 months. Started Jul 2014; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02231229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231229.